The study explored the potential of HMGA2 gene expression as a molecular marker to differentiate between benign and malignant thyroid nodules in patients with indeterminate fine-needle aspiration cytology.
Analyzing 237 preoperative thyroid samples, the study found that HMGA2 had high sensitivity (91.9%) and negative predictive value (98.2%) for identifying malignant cases, indicating its effectiveness.
Results showed HMGA2 was most positive in papillary and follicular carcinoma samples, suggesting it could be a valuable adjunct in the cytological evaluation of thyroid nodules.